The past year alone has resulted in numerous, public collaborations and deals in personalized, or precision medicine. Many times, these deals are forged late, when the diagnostic is already developed or the drug is already without a biomarker, the clinical algorithm is already too complex or the technology is not accessible in the majority of the countries in need, or the deal is forged in haste without the proper diligence assessment to protect investment. Knowing when and what to bring to the table as a partner is the base of success in global precision medicine, and this session will uncover that, plus when one should partner to maximize the success of their companion diagnostic, who they should partner with, and what terms are acceptable to both parties in this ever-changing landscape.
Ability Level: All
Session ID: 2549